NCT01639833CompletedNot Applicable
A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Medtronic - MITG
- Enrollment
- 90
- Locations
- 12
- Primary Endpoint
- Time to Hemostasis (TTH)
Study Overview
Brief Summary
The objective of this study is to assess the safety and effectiveness of Veriset™ Hemostatic Patch in cardiovascular procedures by comparing Veriset™ Hemostatic Patch to TachoSil® in subjects undergoing open cardiovascular surgery involving the aorta (e.g., aortic valve replacement (AVR), David procedure, Bentall procedure, abdominal aortic aneurysm repair, etc.), or CABG.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject has provided informed consent.
- •Subject is ≥18 years of age.
- •Subject is scheduled for surgery involving the aorta (e.g., aortic valve replacement (AVR), David procedure, Bentall procedure, abdominal aortic aneurysm repair, etc.), or coronary artery bypass graft (CABG) where a topical hemostatic agent would be used to control bleeding via an open approach.
- •Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.
- •Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death.
- •Subject has a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin.
- •Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding.
- •Subject has an estimated life expectancy of less than 6 months.
- •Subject is unwilling to receive blood products.
- •Subject is scheduled for another planned cardiovascular surgery, and subsequent surgery would jeopardize previous application of study treatment.
- •The subject has participated in another investigational drug or device research study within 30 days of enrollment.
Exclusion Criteria
- •Subject has an appropriate Target Bleeding Site (TBS) defined as an area of bleeding on the aorta or coronary vessels where hemostasis by conventional methods is ineffective or impractical, and thus necessitates the use of a topical hemostatic agent.
- •TBS Bleeding is Type 2 (Oozing/Mild) or 3 (Moderate).
- •It is possible to hold pressure on Veriset™ Hemostatic Patch or TachoSil® for at least 3 minutes.
- •Incidental finding of any other pre-operative exclusion criteria
- •Subject does not have an appropriate TBS.
- •TBS Bleeding Assessment is Type 1 (No bleeding) or 4 (Severe/Surgical/Life Threatening).
- •Subject has an active local infection at the surgical site.
- •Investigator determines that participation in the study may jeopardize the safety or welfare of the subject.
Outcomes
Primary Outcomes
Time to Hemostasis (TTH)
Time Frame: Day 0
Time to Hemostasis (TTH) at the target bleeding site (TBS) following treatment (Veriset™ Hemostatic Patch or Control).
Secondary Outcomes
- Hemostasis at All Treated Bleeding Sites Within 3 Minutes(Day 0)
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Completed
Not Applicable
A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft TissueNon-emergent, Soft Tissue Procedures, Performed Via an Open ApproachNCT01719172Medtronic - MITG30
Completed
Phase 3
The EVARREST® Fibrin Sealant Patch Liver StudyHemorrhageNCT01993888Ethicon, Inc.102
Completed
Phase 3
The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding StudyControlling Mild to Moderate Bleeding During SurgeryNCT03255174Ethicon, Inc.35
Completed
Phase 3
Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac SurgeryCardiac Surgery Requiring Cardiopulmonary Bypass and Median SternotomyCardiopulmonary BypassSternotomyNCT00161733Baxter Healthcare Corporation
Completed
Not Applicable
U.S. Study of Fibrocaps in Surgical HemostasisPostoperative HemorrhageNCT01256164Mallinckrodt70